Colin J Henderson

List of Publications by Year
in descending order

123 papers	8,186 citations	61857 43 h-index	49773 87 g-index
134 all docs	134 docs citations	134 times ranked	8898 citing authors

#	Article	IF	Citations
1	Regulation of JNK signaling by GSTp. EMBO Journal, 1999, 18, 1321-1334.	3.5	983
2	Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochemical Journal, 2002, 365, 405-416.	1.7	399
3	Feedback control of AHR signalling regulates intestinal immunity. Nature, 2017, 542, 242-245.	13.7	381
4	Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 5275-5280.	3.3	366
5	Uptake and effects of orally ingested polystyrene microplastic particles in vitro and in vivo. Archives of Toxicology, 2019, 93, 1817-1833.	1.9	318
6	The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochemical Society Transactions, 2000, 28, 33-41.	1.6	305
7	Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19589-19594.	3.3	255
8	Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase. Journal of Biological Chemistry, 2003, 278, 13480-13486.	1.6	233
9	Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. Journal of Lipid Research, 2016, 57, 2130-2137.	2.0	221
10	Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 12741-12745.	3.3	210
11	Transcription Factor Nrf2 Is Essential for Induction of NAD(P)H:Quinone Oxidoreductase 1, Glutathione S-Transferases, and Glutamate Cysteine Ligase by Broccoli Seeds and Isothiocyanates. Journal of Nutrition, 2004, 134, 3499S-3506S.	1.3	181
12	Identification of Novel Roles of the Cytochrome P450 System in Early Embryogenesis: Effects on Vasculogenesis and Retinoic Acid Homeostasis. Molecular and Cellular Biology, 2003, 23, 6103-6116.	1.1	168
13	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 348, 332-7.	1.4	163
14	Human Constitutive Androstane Receptor (CAR) and Pregnane X Receptor (PXR) Support the Hypertrophic but not the Hyperplastic Response to the Murine Nongenotoxic Hepatocarcinogens Phenobarbital and Chlordane In Vivo. Toxicological Sciences, 2010, 116, 452-466.	1.4	137
15	Increased Constitutive c-Jun N-terminal Kinase Signaling in Mice Lacking Glutathione S-Transferase Pi. Journal of Biological Chemistry, 2003, 278, 22243-22249.	1.6	134
16	High variability of nitrosamine metabolism among individuals: Role of cytochromes P450 2A6 and 2E1 in the dealkylation ofN-nitrosodimethylamine andN-nitrosodiethylamine in mice and humans. Molecular Carcinogenesis, 1993, 7, 268-275.	1.3	127
17	Environmental Pollutant and Potent Mutagen 3-Nitrobenzanthrone Forms DNA Adducts after Reduction by NAD(P)H:Quinone Oxidoreductase and Conjugation by Acetyltransferases and Sulfotransferases in Human Hepatic Cytosols. Cancer Research, 2005, 65, 2644-2652.	0.4	118
18	Role of Hepatic Cytochrome P450s in the Pharmacokinetics and Toxicity of Cyclophosphamide: Studies with the Hepatic Cytochrome P450 Reductase Null Mouse. Cancer Research, 2005, 65, 4211-4217.	0.4	117

#	Article	IF	Citations
19	Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis, 2007, 29, 656-665.	1.3	115
20	A General Strategy for the Expression of Recombinant Human Cytochrome P450s inEscherichia coliUsing Bacterial Signal Peptides: Expression of CYP3A4, CYP2A6, and CYP2E1. Archives of Biochemistry and Biophysics, 1997, 345, 342-354.	1.4	106
21	Pi-class glutathione S-transferase: regulation and function. Chemico-Biological Interactions, 1998, 111-112, 69-82.	1.7	97
22	Polarization lidar measurements of honey bees in flight for locating land mines. Optics Express, 2005, 13, 5853.	1.7	94
23	Glutathione Transferase Ï€ Plays a Critical Role in the Development of Lung Carcinogenesis following Exposure to Tobacco-Related Carcinogens and Urethane. Cancer Research, 2007, 67, 9248-9257.	0.4	75
24	Defining the in Vivo Role for Cytochrome b5 in Cytochrome P450 Function through the Conditional Hepatic Deletion of Microsomal Cytochrome b5. Journal of Biological Chemistry, 2008, 283, 31385-31393.	1.6	75
25	Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway. Biochemical Journal, 2009, 417, 43-58.	1.7	74
26	Aryl hydrocarbon receptor is required for optimal Bâ€cell proliferation. EMBO Journal, 2017, 36, 116-128.	3.5	74
27	GSTÂ expression mediates dopaminergic neuron sensitivity in experimental parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1977-1982.	3.3	73
28	Markedly enhanced colon tumorigenesis in Apc ^{Min} mice lacking glutathione S-transferase Pi. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20859-20864.	3.3	66
29	Deletion of Microsomal Cytochromeb₅Profoundly Affects Hepatic and Extrahepatic Drug Metabolism. Molecular Pharmacology, 2010, 78, 269-278.	1.0	64
30	Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochemical Pharmacology, 1995, 49, 1035-1042.	2.0	62
31	Evidence That Cytochrome b5 and Cytochrome b5 Reductase Can Act as Sole Electron Donors to the Hepatic Cytochrome P450 System. Molecular Pharmacology, 2013, 83, 1209-1217.	1.0	62
32	Rescue of cytochrome P450 oxidoreductase (Por) mouse mutants reveals functions in vasculogenesis, brain and limb patterning linked to retinoic acid homeostasis. Developmental Biology, 2007, 303, 66-81.	0.9	61
33	Phenobarbital Induces Cell Cycle Transcriptional Responses in Mouse LiverÂHumanized for ConstitutiveÂAndrostane and Pregnane X Receptors. Toxicological Sciences, 2014, 139, 501-511.	1.4	60
34	Cholesterol Metabolism: the Main Pathway Acting Downstream of Cytochrome P450 Oxidoreductase in Skeletal Development of the Limb. Molecular and Cellular Biology, 2009, 29, 2716-2729.	1.1	58
35	Cellular Response to a GlutathioneS-Transferase P1-1 Activated Prodrug. Molecular Pharmacology, 2000, 58, 167-174.	1.0	57
36	Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (POR) null mice. Biochemical Journal, 2005, 388, 857-867.	1.7	56

#	Article	IF	Citations
37	Role of Cytochromes P450 1A1/2 in Detoxication and Activation of Carcinogenic Aristolochic Acid I: Studies with the Hepatic NADPH:Cytochrome P450 Reductase Null (HRN) Mouse Model. Toxicological Sciences, 2011, 121, 43-56.	1.4	56
38	Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. Cancer Letters, 2006, 234, 220-231.	3.2	55
39	Phenobarbital-Mediated Tumor Promotion in Transgenic Mice with Humanized CAR and PXR. Toxicological Sciences, 2014, 140, 259-270.	1.4	50
40	Glutathione S-Transferase pi Mediates MPTP-Induced c-Jun N-Terminal Kinase Activation in the Nigrostriatal Pathway. Molecular Neurobiology, 2012, 45, 466-477.	1.9	46
41	Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochemical Pharmacology, 1992, 44, 617-620.	2.0	44
42	Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: Studies with the hepatic NADPH:Cytochrome P450 reductase null mouse. Toxicology and Applied Pharmacology, 2008, 226, 318-327.	1.3	44
43	The Involvement of Mitochondrial Amidoxime Reducing Components 1 and 2 and Mitochondrial Cytochrome b5 in N-Reductive Metabolism in Human Cells. Journal of Biological Chemistry, 2013, 288, 20228-20237.	1.6	44
44	Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions. Toxicology, 2014, 318, 1-12.	2.0	41
45	Analysis of the biological properties of antibodies raised against intact and deglycosylated porcine zonae pellucidae. Gamete Research, 1987, 16, 323-341.	1.7	40
46	Disruption of the Glutathione Transferase Pi Class Genes. Methods in Enzymology, 2005, 401, 116-135.	0.4	40
47	The Role of Protein-Protein and Protein-Membrane Interactions on P450 Function. Drug Metabolism and Disposition, 2016, 44, 576-590.	1.7	39
48	Protein expression profiling of glutathione S-transferase pi null mice as a strategy to identify potential markers of resistance to paracetamol-induced toxicity in the liver. Proteomics, 2003, 3, 191-207.	1.3	38
49	The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. Toxicology Letters, 2006, 162, 111-117.	0.4	38
50	Functional Expression and Comparative Characterization of Nine Murine Cytochromes P450 by Fluorescent Inhibition Screening. Drug Metabolism and Disposition, 2008, 36, 1322-1331.	1.7	37
51	Conditional Deletion of Cytochrome P450 Oxidoreductase in the Liver and Gastrointestinal Tract: A New Model for Studying the Functions of the P450 System. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 40-47.	1.3	35
52	In Vivo Regulation of Human Glutathione Transferase GSTP by Chemopreventive Agents. Cancer Research, 2014, 74, 4378-4387.	0.4	35
53	Deduced amino acid sequence of a murine cytochrome P-450 Cyp4a protein: developmental and hornonal regulation in liver and kidney. Biochimica Et Biophysica Acta - General Subjects, 1994, 1200, 182-190.	1.1	33
54	Knockout and transgenic mice in glutathione transferase research. Drug Metabolism Reviews, 2011, 43, 152-164.	1.5	33

#	Article	IF	Citations
55	Pyrethroid activity-based probes for profiling cytochrome P450 activities associated with insecticide interactions. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19766-19771.	3.3	33
56	Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice. Drug Metabolism and Disposition, 2019, 47, 907-918.	1.7	33
57	The pyrrolizidine alkaloid senecionine induces CYP-dependent destruction of sinusoidal endothelial cells and cholestasis in mice. Archives of Toxicology, 2020, 94, 219-229.	1.9	33
58	Attenuation of lung fibrosis in mice with a clinically relevant inhibitor of glutathione-S-transferase Ï€. JCI Insight, 2016, 1, .	2.3	32
59	Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling. Toxicology Letters, 2012, 213, 160-166.	0.4	31
60	Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer. British Journal of Cancer, 2016, 115, 1530-1539.	2.9	31
61	Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenetics and Genomics, 2009, 19, 565-566.	0.7	30
62	Cytochromeb₅Is a Major Determinant of Human Cytochrome P450 CYP2D6 and CYP3A4 Activity In Vivo. Molecular Pharmacology, 2015, 87, 733-739.	1.0	30
63	Polyclonal antibodies to a 32-KDA deglycosylated polypeptide from porcine zonae pellucidae will prevent human gamete interaction in vitro. Gamete Research, 1987, 18, 251-265.	1.7	29
64	Glutathione Transferase P1. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1202-1210.	2.5	29
65	Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 12-19.	1.3	29
66	The Murine Cyp1a1 Gene Is Expressed in a Restricted Spatial and Temporal Pattern during Embryonic Development. Journal of Biological Chemistry, 2005, 280, 5828-5835.	1.6	26
67	Development of a Liquid Chromatographyâ€“Electrospray Ionization Tandem Mass Spectrometry Method for Detecting Oxaliplatinâ€“DNA Intrastrand Cross-Links in Biological Samples. Chemical Research in Toxicology, 2007, 20, 1177-1182.	1.7	26
68	Proteome-wide identification and quantification of S-glutathionylation targets in mouse liver. Biochemical Journal, 2015, 469, 25-32.	1.7	26
69	Cytochrome b 5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b 5 /P450 reductase null (HBRN) mice. Archives of Toxicology, 2018, 92, 1625-1638.	1.9	26
70	Correlation between 3-MCPD-induced organ toxicity and oxidative stress response in male mice. Food and Chemical Toxicology, 2020, 136, 110957.	1.8	26
71	Cytochrome b 5 null mouse: a new model for studying inherited skin disorders and the role of unsaturated fatty acids in normal homeostasis. Transgenic Research, 2011, 20, 491-502.	1.3	25
72	Ubiquitinâ€“Proteasome System Impairment and MPTP-Induced Oxidative Stress in the Brain of C57BL/6 Wild-type and GSTP Knockout Mice. Molecular Neurobiology, 2013, 47, 662-672.	1.9	25

#	Article	IF	Citations
73	Altered Protein S-Glutathionylation Identifies a Potential Mechanism of Resistance to Acetaminophen-Induced Hepatotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 137-144.	1.3	25
74	Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse. Molecular Cancer Research, 2016, 14, 1195-1203.	1.5	24
75	The Disruption of Hepatic Cytochrome P450 Reductase Alters Mouse Lipid Metabolism. Journal of Proteome Research, 2007, 6, 3976-3984.	1.8	23
76	Activation Status of the Pregnane X Receptor Influences Vemurafenib Availability in Humanized Mouse Models. Cancer Research, 2015, 75, 4573-4581.	0.4	23
77	Transgenic Analysis of Human Drug-Metabolizing Enzymes: Preclinical Drug Development and Toxicology. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2003, 3, 331-343.	3.4	23
78	Glutathione-S-transferase P promotes glycolysis in asthma in association with oxidation of pyruvate kinase M2. Redox Biology, 2021, 47, 102160.	3.9	23
79	The Imidazoacridinone Antitumor Drug, C-1311, Is Metabolized by Flavin Monooxygenases but Not by Cytochrome P450s. Drug Metabolism and Disposition, 2011, 39, 1423-1432.	1.7	22
80	Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse Model. Drug Metabolism and Disposition, 2015, 43, 1679-1690.	1.7	22
81	Measuring in vivo responses to endogenous and exogenous oxidative stress using a novel haem oxygenase 1 reporter mouse. Journal of Physiology, 2018, 596, 105-127.	1.3	22
82	HDAC Inhibitors Increase NRF2-Signaling in Tumour Cells and Blunt the Efficacy of Co-Adminstered Cytotoxic Agents. PLoS ONE, 2014, 9, e114055.	1.1	21
83	Deletion of 30 Murine Cytochrome P450 Genes Results In Viable Mice With Compromised Drug Metabolism. Drug Metabolism and Disposition, 2014, 42, 1022-1030.	1.7	21
84	Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis (cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. Biochemical and Biophysical Research Communications, 2015, 465, 402-407.	1.0	21
85	Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy. Clinical Cancer Research, 2018, 24, 2138-2147.	3.2	21
86	Detection and quantitation of N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine adducts in DNA using online column-switching liquid chromatography tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2155-2162.	1.2	20
87	<title>Training and deployment of honeybees to detect explosives and other agents of harm</title>. , 2002, , .		19
88	Use of Transgenic Animals in Understanding Molecular Mechanisms of Toxicity. Journal of Pharmacy and Pharmacology, 2011, 50, 567-574.	1.2	18
89	Increased Skin Papilloma Formation in Mice Lacking Glutathione Transferase GSTP. Cancer Research, 2011, 71, 7048-7060.	0.4	18
90	A Role for Cytochromeb₅in the In Vivo Disposition of Anticancer and Cytochrome P450 Probe Drugs in Mice. Drug Metabolism and Disposition, 2014, 42, 70-77.	1.7	18

#	Article	IF	Citations
91	Immunodetection of Proteins by Western Blotting. , 1992, 80, 221-234.		16
92	Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability. Biochemical Journal, 2015, 465, 479-488.	1.7	16
93	Knockout Mice in Xenobiotic Metabolism. Drug Metabolism Reviews, 2003, 35, 385-392.	1.5	15
94	Effect of Hepatic Cytochrome P450 (P450) Oxidoreductase Deficiency on 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA Adduct Formation in P450 Reductase Conditional Null Mice. Drug Metabolism and Disposition, 2011, 39, 2169-2173.	1.7	15
95	Hepatic cytochrome P-450 reductase-null mice show reduced transcriptional response to quercetin and reveal physiological homeostasis between jejunum and liver. American Journal of Physiology - Renal Physiology, 2006, 291, G63-G72.	1.6	14
96	Humanizing Ï€-Class Glutathione S-Transferase Regulation in a Mouse Model Alters Liver Toxicity in Response to Acetaminophen Overdose. PLoS ONE, 2011, 6, e25707.	1.1	14
97	Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drugâ€“Drug Interaction with Antidepressants. Drug Metabolism and Disposition, 2017, 45, 17-22.	1.7	14
98	The Hepatic Reductase Null (HRN^{â„¢}) and Reductase Conditional Null (RCN) mouse models as suitable tools to study metabolism, toxicity and carcinogenicity of environmental pollutants. Toxicology Research, 2015, 4, 548-562.	0.9	13
99	Constitutive Androstane Receptor 1 is Constitutively Bound to Chromatin and 'Primed' for Transactivation in Hepatocytes. Molecular Pharmacology, 2019, 95, 97-105.	1.0	12
100	Application of the inÂvivo oxidative stress reporter Hmox1 as mechanistic biomarker of arsenic toxicity. Environmental Pollution, 2021, 270, 116053.	3.7	12
101	Sexual differentiation and regulation of cytochrome P-450-formula> CYP2C7. BBA - Proteins and Proteomics, 1992, 1118, 99-106.	2.1	11
102	Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells. Biochemical Pharmacology, 2012, 84, 30-42.	2.0	10
103	Suppression of multi-drug resistance gene expression in the mouse liver by 1,4-bis[2,(3,5-dichloropyridyloxy)]benzene. International Journal of Cancer, 1994, 58, 550-554.	2.3	9
104	MOLECULAR MECHANISM OF GENOTOXICITY OF THE ENVIRONMENTAL POLLUTANT 3-NITROBENZANTHRONE. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2005, 149, 191-197.	0.2	9
105	Purification of bile acid-binding proteins from rat hepatic cytosol. Use of a photoaffinity label to detect novel Yâ€² binders. Lipids and Lipid Metabolism, 1986, 875, 270-285.	2.6	8
106	A Targeted in Vivo SILAC Approach for Quantification of Drug Metabolism Enzymes: Regulation by the Constitutive Androstane Receptor. Journal of Proteome Research, 2014, 13, 866-874.	1.8	8
107	An Enhanced In Vivo Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) Model for Quantification of Drug Metabolism Enzymes *. Molecular and Cellular Proteomics, 2015, 14, 750-760.	2.5	7
108	Evidence That the Capacity of Nongenotoxic Carcinogens to Induce Oxidative Stress Is Subject to Marked Variability. Toxicological Sciences, 2015, 145, 138-148.	1.4	7

#	Article	IF	Citations
109	Xenobiotic CAR Activators Induce Dlk1-Dio3 Locus Noncoding RNA Expression in Mouse Liver. Toxicological Sciences, 2017, 158, 367-378.	1.4	7
110	Drug-induced chromatin accessibility changes associate with sensitivity to liver tumor promotion. Life Science Alliance, 2019, 2, e201900461.	1.3	6
111	Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling. British Journal of Cancer, 2021, 125, 1552-1560.	2.9	6
112	Editorial: Role of Protein-Protein Interactions in Metabolism: Genetics, Structure, Function. Frontiers in Pharmacology, 2017, 8, 881.	1.6	5
113	Effects of 2-MCPD on oxidative stress in different organs of male mice. Food and Chemical Toxicology, 2020, 142, 111459.	1.8	5
114	Synthesis and characterisation of an iodinated bile-salt derivative for photoaffinity labelling. Lipids and Lipid Metabolism, 1984, 795, 257-264.	2.6	4
115	Application of hepatic cytochrome b/P450 reductase null (HBRN) mice to study the role of cytochrome b in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine. Toxicology and Applied Pharmacology, 2019, 366, 64-74.	1.3	2
116	Advances in the generation of mouse models to elucidate the pathways of drug metabolism in rodents and man. Expert Review of Clinical Pharmacology, 2009, 2, 105-109.	1.3	1
117	Transcriptional regulation of the rat Ntcp and Bsep by PXR and FXR in vivo. Toxicology, 2011, 290, 128.	2.0	1
118	Drug induced changes in the mouse liver epigenome. Toxicology Letters, 2014, 229, S16.	0.4	1
119	Nrf2 activation does not affect adenoma development in a mouse model of colorectal cancer. Communications Biology, 2021, 4, 1081.	2.0	1
120	Non-catalytic mechanisms involved in glutathione S-transferase pi mediated cytoprotection. Toxicology, 2010, 278, 371-372.	2.0	0
121	REMOVED: Non-catalytic mechanisms involved in glutathione S-transferase Pi mediated cytoprotection. Toxicology, 2011, 290, 130.	2.0	0
122	Application of next-generation reporter mouse models to study stress responses in vivo. Toxicology Letters, 2014, 229, S16.	0.4	0
123	Abstract 2933: Application of a mouse model humanized for the major pathways of drug disposition in anticancer drug development and use. , 2019, , .		0